Yeung Yuk Pang, Lo Chung Mau, Liu Chi Leung, Wong Benjamin C, Fan Sheung Tat, Wong John
Department of Surgery, Kwong Wah Hospital, and Centre for the Study of Liver Disease, China.
Am J Gastroenterol. 2005 Sep;100(9):1995-2004. doi: 10.1111/j.1572-0241.2005.00229.x.
Hepatocellular carcinoma (HCC) is common in Asia, and the majority are not suitable for curative surgical treatment. We studied the natural history of untreated nonsurgical HCC to examine whether the prognosis has changed with improved supportive treatment and to identify factors affecting survival.
One hundred and six ethnic Chinese patients with HCC not amenable to curative treatment were managed symptomatically as control-arm patients in three randomized studies conducted between January 1996 and April 2001. Seventy-six (71.7%) patients were positive for hepatitis B surface antigen (HBsAg). Prognostic variables for survival were identified by univariate analysis and were subjected to a multivariate Cox analysis to identify the independent predictors of survival.
All but four patients were followed until death. Common causes of death were tumor progression (63.2%) and liver failure (31.1%). The overall median survival was 3 months, and the 1-yr survival was 7.8% only. The median survival of patients of Okuda stages I, II, and III were 5.1 months, 2.7 months, and 1.0 month, respectively (p < 0.05 for comparison between any two stages). Multivariate analysis revealed four independent prognostic variables, namely, serum bilirubin, blood urea, serum alpha-fetoprotein, and Okuda stage.
The prognosis of untreated HCC not suitable for curative treatment in Asia is grave despite improved supportive treatment. The four prognostic variables identified in this study are important in the decision for palliative treatment, and the Okuda staging remains an important prognostic guide.
肝细胞癌(HCC)在亚洲较为常见,且大多数患者不适合进行根治性手术治疗。我们研究了未经治疗的非手术HCC的自然病程,以探讨随着支持治疗的改善预后是否发生了变化,并确定影响生存的因素。
1996年1月至2001年4月期间进行的三项随机研究中,106例不适合进行根治性治疗的华裔HCC患者作为对照臂患者接受了对症治疗。76例(71.7%)患者乙肝表面抗原(HBsAg)呈阳性。通过单因素分析确定生存的预后变量,并进行多因素Cox分析以确定生存的独立预测因素。
除4例患者外,所有患者均随访至死亡。常见死亡原因是肿瘤进展(63.2%)和肝衰竭(31.1%)。总体中位生存期为3个月,1年生存率仅为7.8%。奥田分期I、II和III期患者的中位生存期分别为5.1个月、2.7个月和1.0个月(任意两个分期之间比较,p<0.05)。多因素分析显示四个独立的预后变量,即血清胆红素、血尿素、血清甲胎蛋白和奥田分期。
尽管支持治疗有所改善,但亚洲不适合进行根治性治疗的未经治疗的HCC预后仍然很差。本研究确定的四个预后变量在姑息治疗决策中很重要,奥田分期仍然是重要的预后指导。